Replies to post #131661 on Biotech Values

[jellybean]

Yes, this changes the patent landscape. AMGN did a fantastic job protecting their Epogen franchise from infringement and I imagine they will do the same for Enbrel. Inventing around the IP will require real science and not a generic makeover.